Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction

被引:325
|
作者
Zhao, Ende [1 ,2 ]
Maj, Tomasz [1 ]
Kryczek, Ilona [1 ]
Li, Wei [1 ,2 ]
Wu, Ke [1 ,2 ]
Zhao, Lili [3 ]
Wei, Shuang [1 ]
Crespo, Joel [1 ]
Wan, Shanshan [1 ]
Vatan, Linda [1 ]
Szeliga, Wojciech [1 ]
Shao, Irene [1 ]
Wang, Yin [1 ]
Liu, Yan [1 ]
Varambally, Sooryanarayana [4 ,5 ]
Chinnaiyan, Arul M. [5 ]
Welling, Theodore H. [1 ]
Marquez, Victor [6 ]
Kotarski, Jan [7 ]
Wang, Hongbo [8 ]
Wang, Zehua [8 ]
Zhang, Yi [9 ]
Liu, Rebecca [10 ]
Wang, Guobin
Zou, Weiping [1 ,11 ,12 ]
机构
[1] Univ Michigan, Sch Med, Dept Surg, Ann Arbor, MI 48109 USA
[2] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Surg, Wuhan 430074, Peoples R China
[3] Univ Michigan, Sch Med, Dept Biostat, Ann Arbor, MI USA
[4] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA
[5] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI USA
[6] NCI, Ctr Canc Res, Biol Chem Lab, Frederick, MD 21701 USA
[7] Med Univ Lublin, Dept Gynecol Oncol & Gynecol 1, Lublin, Poland
[8] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Obstet & Gynecol, Wuhan 430074, Peoples R China
[9] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI USA
[10] Univ Michigan, Sch Med, Dept Obstet & Gynecol, Ann Arbor, MI USA
[11] Univ Michigan, Grad Programs Immunol & Canc Biol, Ann Arbor, MI 48109 USA
[12] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
基金
美国国家卫生研究院;
关键词
HISTONE METHYLTRANSFERASE EZH2; GROUP PROTEIN EZH2; TH17; CELLS; SURVIVAL; EXPRESSION; STEMNESS; DIFFERENTIATION; METHYLATION; REPRESSION; INHIBITOR;
D O I
10.1038/ni.3313
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Aerobic glycolysis regulates T cell function. However, whether and how primary cancer alters T cell glycolytic metabolism and affects tumor immunity in cancer patients remains a question. Here we found that ovarian cancers imposed glucose restriction on T cells and dampened their function via maintaining high expression of microRNAs miR-101 and miR-26a, which constrained expression of the methyltransferase EZH2. EZH2 activated the Notch pathway by suppressing Notch repressors Numb and Fbxw7 via trimethylation of histone H3 at Lys27 and, consequently, stimulated T cell polyfunctional cytokine expression and promoted their survival via Bcl-2 signaling. Moreover, small hairpin RNA-mediated knockdown of human EZH2 in T cells elicited poor antitumor immunity. EZH2(+)CD8(+) T cells were associated with improved survival in patients. Together, these data unveil a metabolic target and mechanism of cancer immune evasion.
引用
收藏
页码:95 / +
页数:11
相关论文
共 50 条
  • [31] Discovery of precision targeting EZH2 degraders for triple-negative breast cancer
    Wang, Cheng
    Chen, Xinye
    Liu, Xingchen
    Lu, Dehua
    Li, Shang
    Qu, Lailiang
    Yin, Fucheng
    Luo, Heng
    Zhang, Yonglei
    Luo, Zhongwen
    Cui, Ningjie
    Kong, Lingyi
    Wang, Xiaobing
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 238
  • [32] microRNA-214 suppresses the growth of cervical cancer cells by targeting EZH2
    Yang, Yanling
    Liu, Yang
    Li, Guilin
    Li, Lei
    Geng, Peng
    Song, Hongjuan
    ONCOLOGY LETTERS, 2018, 16 (05) : 5679 - 5686
  • [33] EZH2 Downregulation Augments the Effect of Irradiation in Reducing Pancreatic Cancer Cell Proliferation in vitro
    Agrawal, Raag
    Chen, Michael
    Bukhari, Zaheer
    Ogunwobi, Olorunseun O.
    Haseeb, M. A.
    Martello, Laura A.
    ANNALS OF CLINICAL AND LABORATORY SCIENCE, 2020, 50 (01) : 45 - 56
  • [34] Polycomb Protein EZH2 Regulates Tumor Invasion via the Transcriptional Repression of the Metastasis Suppressor RKIP in Breast and Prostate Cancer
    Ren, Gang
    Baritaki, Stavroula
    Marathe, Himangi
    Feng, Jingwei
    Park, Sungdae
    Beach, Sandy
    Bazeley, Peter S.
    Beshir, Anwar B.
    Fenteany, Gabriel
    Mehra, Rohit
    Daignault, Stephanie
    Al-Mulla, Fahd
    Keller, Evan
    Bonavida, Ben
    de la Serna, Ivana
    Yeung, Kam C.
    CANCER RESEARCH, 2012, 72 (12) : 3091 - 3104
  • [35] Targeting PRAME directly or via EZH2 inhibition overcomes retinoid resistance and represents a novel therapy for keratinocyte carcinoma
    Ramchatesingh, Brandon
    Martinez Villarreal, Amelia
    Lefrancois, Philippe
    Gantchev, Jennifer
    Sivachandran, Sriraam
    Abou Setah, Samy
    Litvinov, Ivan V.
    MOLECULAR ONCOLOGY, 2025,
  • [36] The YB-1/EZH2/amphiregulin signaling axis mediates LPA-induced breast cancer cell invasion
    Cho, Kyung Hwa
    Jeong, Bo Young
    Park, Chang Gyo
    Lee, Hoi Young
    ARCHIVES OF PHARMACAL RESEARCH, 2019, 42 (06) : 519 - 530
  • [37] MicroRNA-506 suppresses tumor proliferation and metastasis in colon cancer by directly targeting the oncogene EZH2
    Zhang, Yi
    Lin, Changwei
    Liao, Guoqing
    Liu, Sheng
    Ding, Jie
    Tang, Fang
    Wang, Zhenran
    Liang, Xingsi
    Li, Bo
    Wei, Yangchao
    Huang, Qi
    Li, Xuan
    Tang, Bo
    ONCOTARGET, 2015, 6 (32): : 32586 - 32601
  • [38] The Toxoplasma effector TEEGR promotes parasite persistence by modulating NF-κB signalling via EZH2
    Braun, Laurence
    Brenier-Pinchart, Marie-Pierre
    Hammoudi, Pierre-Mehdi
    Cannella, Dominique
    Kieffer-Jaquinod, Sylvie
    Voltaire, Julien
    Josserand, Veronique
    Touquet, Bastien
    Coute, Yohann
    Tardieux, Isabelle
    Bougdour, Alexandre
    Hakimi, Mohamed-Ali
    NATURE MICROBIOLOGY, 2019, 4 (07) : 1208 - 1220
  • [39] Inhibition of EZH2 exerts antitumorigenic effects in renal cell carcinoma via LATS1
    Hong, Seong Hwi
    Hwang, Hyun Ji
    Son, Da Hyeon
    Kim, Eun Song
    Park, Sung Yul
    Yoon, Young Eun
    FEBS OPEN BIO, 2023, 13 (04): : 724 - 735
  • [40] MELK mediates the stability of EZH2 through site-specific phosphorylation in extranodal natural killer/T-cell lymphoma
    Li, Boheng
    Yan, Junli
    The Phyu
    Fan, Shuangyi
    Chung, Tae-Hoon
    Mustafa, Nurulhuda
    Lin, Baohong
    Wang, Lingzhi
    Eichhorn, Pieter Johan Adam
    Goh, Boon-Cher
    Ng, Siok-Bian
    Kappei, Dennis
    Chng, Wee-Joo
    BLOOD, 2019, 134 (23) : 2046 - 2058